ArticleEuropean journal of medical research2026
Silencing myeloid cell leukemia-1 improves apoptotic and ferroptotic responses in melanoma.
Article in European journal of medical research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundMelanoma is a highly malignant skin cancer characterized by strong metastatic and invasive capabilities. Integrative transcriptomic profiling offers a systematic route to uncover tumor-specific regulatory hubs that could expose new therapeutic vulnerabilities. By combining multi-cohort bioinformatics screening with mechanistic cell-based assays, we sought to delineate critical drivers of disease progression in melanoma.
methodsAn integrative analysis of three GEO microarray cohorts (GSE3189, GSE46517, GSE114445) identified hub genes through differential-expression filtering, protein-protein interaction mapping, and CytoHubba ranking. MCL1 was prioritized as the top network hub, prompting its selection for functional validation. B16F1 murine melanoma cells were transfected with MCL1-specific siRNA or a non-targeting control. Cell viability (CCK-8), scratch-wound migration, adhesion, Annexin V/PI apoptosis, cell-cycle distribution, and reactive-oxygen species (ROS) were quantified. Western blots probed apoptosis, cell cycle, and ferroptosis-related proteins; glutathione (GSH) and malondialdehyde (MDA) were measured by ELISA; mitochondrial ultrastructure was examined by transmission electron microscopy. Ferrostatin-1 (Fer-1) was used to assess the functional relevance of ferroptosis.
resultsIn silico analysis prioritized MCL1 as the top hub within a 136-gene melanoma consensus signature. siRNA achieved > 80% knock-down of Mcl-1 mRNA and protein in B16F1 cells, resulting in: (i) significant reductions in cell viability, migration, and adhesion; (ii) substantial elevation of apoptosis with upregulating Bax, downregulating Bcl-2 and caspase-9/3 activation; (iii) G1-phase arrest accompanied by p53/p21 upregulation; and (iv) a ferroptotic phenotype typified by GSH depletion, MDA/ROS accumulation, mitochondrial swelling, reduced GPX4/SLC7A11 ratio, and higher ACSL4/NCOA4 ratio. Fer-1 partially rescued these molecular alterations yet did not fully restore growth, indicating that Mcl-1 coordinates both caspase-dependent apoptosis and lipid peroxidation-driven ferroptosis in melanoma.
conclusionsOverall, our findings pinpoint that Mcl-1 operates as a multifaceted survival node in melanoma, concurrently sustaining proliferation, migration, and redox homeostasis while suppressing apoptotic and ferroptotic death programs. Dual targeting of Mcl-1 and the ferroptosis pathway may offer a robust therapeutic strategy against melanoma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.